Leap Therapeutics To Participate At The 43Rd Annual J.P. Morgan Healthcare Conference

2025-01-06 07:16:56

(MENAFN- PR Newswire)

CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 43rd Annual J.P. Morgan Healthcare conference in San Francisco, CA.

Leap Presentation Details:

43rd Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 15, 2025
Time: 2:15 p.m. Pacific Time

A live webcast of the presentation may be accessed on the Investors page of the company's website at , where a replay of the events will also be available for a limited time.

About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX ) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit
or view our public filings with the SEC that are available via EDGAR at
or via .

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
[email protected]
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
[email protected]

SOURCE Leap Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN06012025003732001241ID1109058690

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.